Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Expanding the concept of chemically programmable antibodies to RNA aptamers: chemically programmed biotherapeutics.

Literature DB >> 20645365

Expanding the concept of chemically programmable antibodies to RNA aptamers: chemically programmed biotherapeutics.

Ulrich Wuellner¹, Julia I Gavrilyuk, Carlos F Barbas.

Abstract

Entities: CellLine Chemical Disease Gene Species

Mesh：

Substances：

Year: 2010 PMID： 20645365 PMCID： PMC3037263 DOI： 10.1002/anie.201001736

Source DB: PubMed Journal: Angew Chem Int Ed Engl ISSN： 1433-7851 Impact factor: 15.336

× No keyword cloud information.

58 in total

1. Multiple event activation of a generic prodrug trigger by antibody catalysis.

Authors: D Shabat; C Rader; B List; R A Lerner; C F Barbas
Journal: Proc Natl Acad Sci U S A Date: 1999-06-08 Impact factor: 11.205

2. Immune versus natural selection: antibody aldolases with enzymic rates but broader scope.

Authors: C F Barbas; A Heine; G Zhong; T Hoffmann; S Gramatikova; R Björnestedt; B List; J Anderson; E A Stura; I A Wilson; R A Lerner
Journal: Science Date: 1997-12-19 Impact factor: 47.728

3. Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro.

Authors: Yaning Wang; David Fei; Martin Vanderlaan; An Song
Journal: Angiogenesis Date: 2005-05-09 Impact factor: 9.596

4. Liposome-anchored vascular endothelial growth factor aptamers.

Authors: M C Willis; B D Collins; T Zhang; L S Green; D P Sebesta; C Bell; E Kellogg; S C Gill; A Magallanez; S Knauer; R A Bendele; P S Gill; N Janjić; B Collins
Journal: Bioconjug Chem Date: 1998 Sep-Oct Impact factor: 4.774

5. Application of locked nucleic acids to improve aptamer in vivo stability and targeting function.

Authors: Kathrin S Schmidt; Sandra Borkowski; Jens Kurreck; Andrew W Stephens; Rolf Bald; Maren Hecht; Matthias Friebe; Ludger Dinkelborg; Volker A Erdmann
Journal: Nucleic Acids Res Date: 2004-10-27 Impact factor: 16.971

6. VEGF(165) mediates glomerular endothelial repair.

Authors: T Ostendorf; U Kunter; F Eitner; A Loos; H Regele; D Kerjaschki; D D Henninger; N Janjic; J Floege
Journal: J Clin Invest Date: 1999-10 Impact factor: 14.808

7. Pharmacokinetics and biodistribution of novel aptamer compositions.

Authors: Judith M Healy; Scott D Lewis; Markus Kurz; Ryan M Boomer; Kristin M Thompson; Charles Wilson; Thomas G McCauley
Journal: Pharm Res Date: 2004-12 Impact factor: 4.200

8. An efficient chemical approach to bispecific antibodies and antibodies of high valency.

Authors: Julia I Gavrilyuk; Ulrich Wuellner; Syed Salahuddin; Rajib K Goswami; Subhash C Sinha; Carlos F Barbas
Journal: Bioorg Med Chem Lett Date: 2009-05-18 Impact factor: 2.823

9. In vivo properties of an anti-GnRH Spiegelmer: an example of an oligonucleotide-based therapeutic substance class.

Authors: Britta Wlotzka; Susanne Leva; Bernd Eschgfäller; Jens Burmeister; Frank Kleinjung; Christine Kaduk; Peter Muhn; Holger Hess-Stumpp; Sven Klussmann
Journal: Proc Natl Acad Sci U S A Date: 2002-06-17 Impact factor: 11.205

10. Pharmacokinetics and biodistribution of a nucleotide-based thrombin inhibitor in rats.

Authors: L Reyderman; S Stavchansky
Journal: Pharm Res Date: 1998-06 Impact factor: 4.200

12 in total

1. A remote arene-binding site on prostate specific membrane antigen revealed by antibody-recruiting small molecules.

Authors: Andrew X Zhang; Ryan P Murelli; Cyril Barinka; Julien Michel; Alexandra Cocleaza; William L Jorgensen; Jacek Lubkowski; David A Spiegel
Journal: J Am Chem Soc Date: 2010-09-15 Impact factor: 15.419

2. Preparation and activities of macromolecule conjugates of the CCR5 antagonist Maraviroc.

Authors: Shigehiro Asano; Julia Gavrilyuk; Dennis R Burton; Carlos F Barbas
Journal: ACS Med Chem Lett Date: 2014-02-13 Impact factor: 4.345

Review 3. Chemically programmed antibodies.

Authors: Christoph Rader
Journal: Trends Biotechnol Date: 2014-03-11 Impact factor: 19.536

Expanding the concept of chemically programmable antibodies to RNA aptamers: chemically programmed biotherapeutics.

1. Multiple event activation of a generic prodrug trigger by antibody catalysis.

2. Immune versus natural selection: antibody aldolases with enzymic rates but broader scope.

3. Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro.

4. Liposome-anchored vascular endothelial growth factor aptamers.

5. Application of locked nucleic acids to improve aptamer in vivo stability and targeting function.

6. VEGF(165) mediates glomerular endothelial repair.

7. Pharmacokinetics and biodistribution of novel aptamer compositions.

8. An efficient chemical approach to bispecific antibodies and antibodies of high valency.

9. In vivo properties of an anti-GnRH Spiegelmer: an example of an oligonucleotide-based therapeutic substance class.

10. Pharmacokinetics and biodistribution of a nucleotide-based thrombin inhibitor in rats.

1. A remote arene-binding site on prostate specific membrane antigen revealed by antibody-recruiting small molecules.

2. Preparation and activities of macromolecule conjugates of the CCR5 antagonist Maraviroc.

Review 3. Chemically programmed antibodies.

4. Programmable self-assembly of antibody-oligonucleotide conjugates as small molecule and protein carriers.

5. N-Sulfonyl-β-lactam hapten as an effective labeling reagent for aldolase mAb.

Review 6. Antibody-recruiting molecules: an emerging paradigm for engaging immune function in treating human disease.

7. Antibody conjugation approach enhances breadth and potency of neutralization of anti-HIV-1 antibodies and CD4-IgG.

8. Facile and stabile linkages through tyrosine: bioconjugation strategies with the tyrosine-click reaction.

9. Chemically Programmed Bispecific Antibodies in Diabody Format.

10. Chemically Programmed Antibodies AS HIV-1 Attachment Inhibitors.